WP
BCAX

Woodline Partners’s Bicara Therapeutics BCAX Stock Holding History

Woodline Partners’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.63M Hold
232,690
– – 0.02% 672
2025
Q4 		$3.92M Sell
232,690
-116,000
-33% -$1.98M 0.02% 676
2025
Q3 		$5.51M Hold
348,690
– – 0.03% 540
2025
Q2 		$3.24M Hold
348,690
– – 0.02% 640
2025
Q1 		$4.54M Buy
348,690
+72,998
+26% +$969K 0.03% 533
2024
Q4 		$4.8M Sell
275,692
-2,277
-0.8% -$47.4K 0.03% 492
2024
Q3 		$7.08M Buy
+277,969
New +$7.09M 0.06% 345

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Woodline Partners's BCAX Position: Q1 2026 in Review

Woodline Partners held its Bicara Therapeutics (BCAX) position steady in Q1 2026 at 232,690 shares worth $4.63M. The position accounts for 0.02% of the portfolio, ranked #672.

Woodline Partners first reported a position in BCAX in Q3 2024 and has held it in 7 quarters since. The position peaked at $7.08M in Q3 2024. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Woodline Partners held 232,690 shares of Bicara Therapeutics worth $4.63M as of Q1 2026.
  • Woodline Partners left its Bicara Therapeutics share count unchanged in Q1 2026.
  • Bicara Therapeutics made up 0.02% of Woodline Partners's portfolio in Q1 2026, its #672 holding.
  • Woodline Partners first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Woodline Partners's Bicara Therapeutics position peaked at $7.08M in Q3 2024.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.